PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070507
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070507
Glioblastoma Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of glioblastoma drugs Market
The global glioblastoma drugs market was valued at USD 0.79 billion in 2025 and is projected to grow from USD 0.83 billion in 2026 to USD 1.21 billion by 2034, registering a CAGR of 4.82% during the forecast period. The market growth is primarily driven by the increasing prevalence of glioblastoma, growing investments in oncology drug development, rising adoption of combination therapies, and the expansion of immunotherapy-based treatment pipelines. Despite the aggressive nature of glioblastoma and limited long-term treatment success, pharmaceutical companies continue to invest heavily in innovative therapies aimed at improving patient survival outcomes.
North America dominated the global glioblastoma drugs market in 2025, accounting for 37.97% of the total market revenue due to its advanced neuro-oncology infrastructure, strong clinical trial ecosystem, and high treatment adoption rates.
Market Size and Forecast
- 2025 Market Size: USD 0.79 Billion
- 2026 Market Size: USD 0.83 Billion
- 2034 Market Size: USD 1.21 Billion
- CAGR (2026-2034): 4.82%
The growing burden of brain tumors and increasing research into targeted therapies and immune-based treatments are expected to create sustainable growth opportunities across the forecast period.
Key Market Trends
Rising Focus on Immunotherapy-Based Treatments
One of the most significant trends shaping the glioblastoma drugs market is the increasing development of immunotherapy-based therapies. Traditional treatments such as surgery, radiation, and chemotherapy continue to dominate clinical practice, but their effectiveness remains limited, especially in recurrent disease.
As a result, pharmaceutical companies are increasingly investing in:
- Cancer vaccines
- Cell-based immunotherapies
- Immune checkpoint inhibitors
- Personalized tumor-specific therapies
For example, in December 2025, Imvax announced positive Phase 2b trial results for IGV-001, a patient-specific whole-tumor-cell immunotherapy developed for newly diagnosed glioblastoma patients.
Market Drivers
High Unmet Need for Effective Therapies
Glioblastoma remains one of the most aggressive and difficult-to-treat brain cancers. Existing therapies offer limited survival benefits and recurrence rates remain extremely high.
Growing demand for more effective treatments is encouraging companies to accelerate clinical development activities and seek regulatory support. In October 2025, Myosin Therapeutics received U.S. FDA Fast Track designation for MT-125, highlighting increasing regulatory encouragement for innovative glioblastoma therapies.
Market Restraints
Rapid Treatment Resistance and Disease Recurrence
One of the major barriers to market growth is the rapid development of treatment resistance. Most patients experience disease recurrence even after undergoing surgery, radiation, and chemotherapy.
Resistance to standard therapies such as temozolomide reduces long-term treatment effectiveness and creates significant challenges for developers attempting to demonstrate meaningful survival benefits in clinical trials.
Market Opportunities
Expanding Clinical Pipeline
The market is witnessing substantial pipeline activity, creating long-term growth opportunities. Numerous investigational therapies targeting novel biological pathways are entering clinical development.
In August 2025, Lantern Pharma's subsidiary Starlight Therapeutics received FDA clearance to initiate a Phase Ib/2a clinical study for glioblastoma, reflecting the industry's continued commitment to addressing unmet treatment needs.
Market Challenges
Tumor Heterogeneity
Glioblastoma exhibits significant biological variability among patients and even within individual tumors. This heterogeneity complicates treatment development and reduces the likelihood of a single therapy being effective across the broader patient population.
As a result, drug developers face complex clinical trial designs, increased development risks, and challenges in identifying responsive patient groups.
Segment Analysis
By Drug
The Temozolomide segment dominated the market in 2025 due to its established role as the standard first-line chemotherapy for glioblastoma treatment.
The Others segment is expected to register the fastest growth with a CAGR of 8.50% during the forecast period.
By Drug Class
Alkylating Agents held the largest market share owing to widespread use of temozolomide-based treatment regimens.
The Immune Checkpoint Inhibitors segment is projected to grow at a CAGR of 11.92% through 2034.
By Age Group
The Adult segment dominated the market due to the significantly higher incidence of glioblastoma among adults.
The Pediatric segment is expected to grow at a CAGR of 7.61%.
By Type
The Generic Drugs segment accounted for the largest share due to broad availability and lower treatment costs.
By Therapy
Chemotherapy remained the leading therapy segment in 2025, supported by continued reliance on temozolomide-based treatment protocols.
The Immunotherapy segment is expected to witness the fastest growth at a CAGR of 12.72%.
By Route of Administration
The Oral segment dominated the market because temozolomide is primarily administered orally, improving patient convenience and treatment adherence.
By Distribution Channel
Hospital Pharmacies accounted for the largest market share owing to the specialized nature of glioblastoma treatment and hospital-centered care pathways.
Regional Analysis
North America
- 2025 Market Value: USD 0.30 Billion
- Largest regional market in 2025
The region benefits from advanced healthcare infrastructure, strong oncology research activities, and extensive clinical trial participation.
Europe
- 2026 Market Value: USD 0.23 Billion
Europe continues to expand due to strong public healthcare systems and increasing access to advanced cancer therapies.
Asia Pacific
- 2026 Market Value: USD 0.19 Billion
Growth is supported by improving cancer treatment infrastructure and increasing investments in oncology research.
Key Country Insights (2026)
- U.S.: USD 0.29 Billion
- China: USD 0.08 Billion
- Germany: USD 0.05 Billion
- U.K.: USD 0.05 Billion
- Japan: USD 0.04 Billion
- India: USD 0.02 Billion
Competitive Landscape
The market remains highly consolidated with major players focusing on product launches, clinical trials, partnerships, and pipeline expansion.
Key companies include:
- Merck & Co., Inc.
- Genentech, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Accord Healthcare
- Camber Pharmaceuticals, Inc.
- Fresenius Kabi AG
- Zydus Lifesciences Ltd.
Recent industry developments include multiple clinical trial initiations, FDA designations, novel immunotherapy advancements, and genomic testing collaborations aimed at improving treatment outcomes.
Conclusion
The global glioblastoma drugs market is expected to experience steady growth from USD 0.79 billion in 2025 to USD 1.21 billion by 2034. Rising incidence of brain tumors, increasing investment in immunotherapy and targeted therapies, and a robust clinical pipeline are driving market expansion. While challenges such as tumor heterogeneity, treatment resistance, and high recurrence rates remain significant, continued innovation and regulatory support are expected to improve therapeutic options and create new growth opportunities throughout the forecast period.
Segmentation By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region
By Drug * Temozolomide
- Bevacizumab
- Carmustine
- Lomustine
- Procarbazine
- Irinotecan
- Others
By Drug Class * Alkylating agents
- VEGF / angiogenesis inhibitors
- Nitrosoureas
- Platinum compounds
- Topoisomerase inhibitors
- Immune checkpoint inhibitors
- Others
By Age Group * Pediatric
- Adults
By Type * Branded
- Generic
By Therapy * Targeted Therapy
- Immunotherapy
- Chemotherapy
- Others
By Route of Administration * Oral
- Parenteral
By Distribution Channel * Hospital pharmacies
- Drug stores & retail pharmacies
- Online pharmacies
By Region * North America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Cancer, By Key Indication, By Key Countries /Regions
- 4.2. New Product Launches, By Key Players
- 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
- 4.4. Regulatory Scenario, By Key Countries/Regions
5. Global Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Temozolomide
- 5.1.2. Bevacizumab
- 5.1.3. Carmustine
- 5.1.4. Lomustine
- 5.1.5. Procarbazine
- 5.1.6. Irinotecan
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Drug Class
- 5.2.1. Alkylating Agents
- 5.2.2. VEGF/Angiogenesis Inhibitors
- 5.2.3. Nitrosoureas
- 5.2.4. Platinum Compounds
- 5.2.5. Topoisomerase Inhibitors
- 5.2.6. Immune Checkpoint Inhibitors
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Generic
- 5.5. Market Analysis, Insights and Forecast - By Therapy
- 5.5.1. Targeted therapy
- 5.5.2. Immunotherapy
- 5.5.3. Chemotherapy
- 5.5.4. Others
- 5.6. Market Analysis, Insights and Forecast - By Route of Administration
- 5.6.1. Oral
- 5.6.2. Parenteral
- 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.7.1. Hospital Pharmacies
- 5.7.2. Drug Stores & Retail Pharmacies
- 5.7.3. Online Pharmacies
- 5.8. Market Analysis, Insights and Forecast - Region
- 5.8.1. North America
- 5.8.2. Europe
- 5.8.3. Asia Pacific
- 5.8.4. Latin America
- 5.8.5. Middle East & Africa
6. North America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Temozolomide
- 6.1.2. Bevacizumab
- 6.1.3. Carmustine
- 6.1.4. Lomustine
- 6.1.5. Procarbazine
- 6.1.6. Irinotecan
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Drug Class
- 6.2.1. Alkylating Agents
- 6.2.2. VEGF/Angiogenesis Inhibitors
- 6.2.3. Nitrosoureas
- 6.2.4. Platinum Compounds
- 6.2.5. Topoisomerase Inhibitors
- 6.2.6. Immune Checkpoint Inhibitors
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Generic
- 6.5. Market Analysis, Insights and Forecast - By Therapy
- 6.5.1. Targeted therapy
- 6.5.2. Immunotherapy
- 6.5.3. Chemotherapy
- 6.5.4. Others
- 6.6. Market Analysis, Insights and Forecast - By Route of Administration
- 6.6.1. Oral
- 6.6.2. Parenteral
- 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.7.1. Hospital Pharmacies
- 6.7.2. Drug Stores & Retail Pharmacies
- 6.7.3. Online Pharmacies
- 6.8. Market Analysis, Insights and Forecast - By Country
- 6.8.1. U.S.
- 6.8.2. Canada
7. Europe Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Temozolomide
- 7.1.2. Bevacizumab
- 7.1.3. Carmustine
- 7.1.4. Lomustine
- 7.1.5. Procarbazine
- 7.1.6. Irinotecan
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Drug Class
- 7.2.1. Alkylating Agents
- 7.2.2. VEGF/Angiogenesis Inhibitors
- 7.2.3. Nitrosoureas
- 7.2.4. Platinum Compounds
- 7.2.5. Topoisomerase Inhibitors
- 7.2.6. Immune Checkpoint Inhibitors
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Generic
- 7.5. Market Analysis, Insights and Forecast - By Therapy
- 7.5.1. Targeted therapy
- 7.5.2. Immunotherapy
- 7.5.3. Chemotherapy
- 7.5.4. Others
- 7.6. Market Analysis, Insights and Forecast - By Route of Administration
- 7.6.1. Oral
- 7.6.2. Parenteral
- 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.7.1. Hospital Pharmacies
- 7.7.2. Drug Stores & Retail Pharmacies
- 7.7.3. Online Pharmacies
- 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.8.1. U.K.
- 7.8.2. Germany
- 7.8.3. France
- 7.8.4. Italy
- 7.8.5. Spain
- 7.8.6. Scandinavia
- 7.8.7. Rest of Europe
8. Asia Pacific Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Temozolomide
- 8.1.2. Bevacizumab
- 8.1.3. Carmustine
- 8.1.4. Lomustine
- 8.1.5. Procarbazine
- 8.1.6. Irinotecan
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Drug Class
- 8.2.1. Alkylating Agents
- 8.2.2. VEGF/Angiogenesis Inhibitors
- 8.2.3. Nitrosoureas
- 8.2.4. Platinum Compounds
- 8.2.5. Topoisomerase Inhibitors
- 8.2.6. Immune Checkpoint Inhibitors
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Generic
- 8.5. Market Analysis, Insights and Forecast - By Therapy
- 8.5.1. Targeted therapy
- 8.5.2. Immunotherapy
- 8.5.3. Chemotherapy
- 8.5.4. Others
- 8.6. Market Analysis, Insights and Forecast - By Route of Administration
- 8.6.1. Oral
- 8.6.2. Parenteral
- 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.7.1. Hospital Pharmacies
- 8.7.2. Drug Stores & Retail Pharmacies
- 8.7.3. Online Pharmacies
- 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.8.1. China
- 8.8.2. Japan
- 8.8.3. India
- 8.8.4. Southeast Asia
- 8.8.5. Australia
- 8.8.6. Rest of Asia Pacific
9. Latin America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Temozolomide
- 9.1.2. Bevacizumab
- 9.1.3. Carmustine
- 9.1.4. Lomustine
- 9.1.5. Procarbazine
- 9.1.6. Irinotecan
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Drug Class
- 9.2.1. Alkylating Agents
- 9.2.2. VEGF/Angiogenesis Inhibitors
- 9.2.3. Nitrosoureas
- 9.2.4. Platinum Compounds
- 9.2.5. Topoisomerase Inhibitors
- 9.2.6. Immune Checkpoint Inhibitors
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Generic
- 9.5. Market Analysis, Insights and Forecast - By Therapy
- 9.5.1. Targeted therapy
- 9.5.2. Immunotherapy
- 9.5.3. Chemotherapy
- 9.5.4. Others
- 9.6. Market Analysis, Insights and Forecast - By Route of Administration
- 9.6.1. Oral
- 9.6.2. Parenteral
- 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.7.1. Hospital Pharmacies
- 9.7.2. Drug Stores & Retail Pharmacies
- 9.7.3. Online Pharmacies
- 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.8.1. Brazil
- 9.8.2. Mexico
- 9.8.3. Rest of Latin America
10. Middle East & Africa Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug
- 10.1.1. Temozolomide
- 10.1.2. Bevacizumab
- 10.1.3. Carmustine
- 10.1.4. Lomustine
- 10.1.5. Procarbazine
- 10.1.6. Irinotecan
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Drug Class
- 10.2.1. Alkylating Agents
- 10.2.2. VEGF/Angiogenesis Inhibitors
- 10.2.3. Nitrosoureas
- 10.2.4. Platinum Compounds
- 10.2.5. Topoisomerase Inhibitors
- 10.2.6. Immune Checkpoint Inhibitors
- 10.2.7. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Generic
- 10.5. Market Analysis, Insights and Forecast - By Therapy
- 10.5.1. Targeted therapy
- 10.5.2. Immunotherapy
- 10.5.3. Chemotherapy
- 10.5.4. Others
- 10.6. Market Analysis, Insights and Forecast - By Route of Administration
- 10.6.1. Oral
- 10.6.2. Parenteral
- 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.7.1. Hospital Pharmacies
- 10.7.2. Drug Stores & Retail Pharmacies
- 10.7.3. Online Pharmacies
- 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.8.1. GCC
- 10.8.2. South Africa
- 10.8.3. Rest of the Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck & Co., Inc.
- 11.2.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- 11.2.3. Teva Pharmaceutical Industries Ltd.
- 11.2.4. Sun Pharmaceutical Industries Ltd.
- 11.2.5. Accord Healthcare
- 11.2.6. Camber Pharmaceuticals, Inc.
- 11.2.7. Fresenius Kabi AG
- 11.2.8. Zydus Lifesciences Ltd.
- 11.2.9. Amneal Pharmaceuticals, Inc.
List of Tables
- Figure 1: Global Glioblastoma Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Glioblastoma Drugs Market Value Share (%), By Drug, 2025 & 2034
- Figure 3: Global Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025 & 2034
- Figure 4: Global Glioblastoma Drugs Market Value Share (%), by Age Group, 2025 & 2034
- Figure 5: Global Glioblastoma Drugs Market Value Share (%), by Type, 2025 & 2034
- Figure 6: Global Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 7: Global Glioblastoma Drugs Market Value Share (%), by Therapy, 2025 & 2034
- Figure 8: Global Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 9: Global Glioblastoma Drugs Market Value Share (%), by Region, 2025 & 2034
- Figure 10: North America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 11: North America Glioblastoma Drugs Market Value Share (%), By Drug, 2025
- Figure 12: North America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 13: North America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
- Figure 14: North America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
- Figure 15: North America Glioblastoma Drugs Market Value Share (%), by Age Group 2025
- Figure 16: North America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
- Figure 17: North America Glioblastoma Drugs Market Value Share (%), by Type, 2025
- Figure 18: North America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 19: North America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
- Figure 20: North America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 21: North America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 22: North America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 23: North America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 24: North America Glioblastoma Drugs Market Value (USD billion), by Country, 2025 & 2034
- Figure 25: North America Glioblastoma Drugs Market Value Share (%), by Country, 2025
- Figure 26: Europe Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 27: Europe Glioblastoma Drugs Market Value Share (%), By Drug, 2025
- Figure 28: Europe Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 29: Europe Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
- Figure 30: Europe Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
- Figure 31: Europe Glioblastoma Drugs Market Value Share (%), by Age Group 2025
- Figure 32: Europe Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
- Figure 33: Europe Glioblastoma Drugs Market Value Share (%), by Type, 2025
- Figure 34: Europe Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 35: Europe Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
- Figure 36: Europe Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 37: Europe Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 38: Europe Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 39: Europe Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 40: Europe Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 41: Europe Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 42: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 43: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug, 2025
- Figure 44: Asia Pacific Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 45: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
- Figure 46: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
- Figure 47: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Age Group 2025
- Figure 48: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
- Figure 49: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Type, 2025
- Figure 50: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 51: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
- Figure 52: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 53: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 54: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 55: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 56: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 57: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 58: Latin America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 59: Latin America Glioblastoma Drugs Market Value Share (%), By Drug, 2025
- Figure 60: Latin America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 61: Latin America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
- Figure 62: Latin America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
- Figure 63: Latin America Glioblastoma Drugs Market Value Share (%), by Age Group 2025
- Figure 64: Latin America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
- Figure 65: Latin America Glioblastoma Drugs Market Value Share (%), by Type, 2025
- Figure 66: Latin America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 67: Latin America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
- Figure 68: Latin America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 69: Latin America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 70: Latin America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 71: Latin America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 72: Latin America Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 73: Latin America Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 74: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 75: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug, 2025
- Figure 76: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 77: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025
- Figure 78: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034
- Figure 79: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Age Group 2025
- Figure 80: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034
- Figure 81: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Type, 2025
- Figure 82: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 83: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Therapy, 2025
- Figure 84: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 85: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 86: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 87: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 88: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 89: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 90: Global Glioblastoma Drugs Market Share (%), by Company, 2025
